Biogen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Biogen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. 

CEO
Christopher A. Viehbacher
CEOChristopher A. Viehbacher
Employees
7,605
Employees7,605
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
1978
Founded1978
Employees
7,605
Employees7,605

BIIB Key Statistics

Market cap
19.47B
Market cap19.47B
Price-Earnings ratio
13.12
Price-Earnings ratio13.12
Dividend yield
Dividend yield
Average volume
1.26M
Average volume1.26M
High today
$134.42
High today$134.42
Low today
$132.21
Low today$132.21
Open price
$133.49
Open price$133.49
Volume
619.89K
Volume619.89K
52 Week high
$238.00
52 Week high$238.00
52 Week low
$110.04
52 Week low$110.04

BIIB News

TipRanks 3d
Biogen’s Litifilimab Study: A Long-Term Look at SLE Treatment

Biogen Inc. ((BIIB)), Biogen ((CC:HTER)) announced an update on their ongoing clinical study. Don’t Miss TipRanks’ Half-Year Sale Take advantage of TipRanks P...

Analyst ratings

49%

of 37 ratings
Buy
48.6%
Hold
48.6%
Sell
2.7%

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.